Anti-aging research has shifted away from chasing single biomarkers toward a systems-level view. The "hallmarks of aging" framework — first laid out by López-Otín et al. in Cell (2013) and expanded to twelve converging processes in the 2023 update — gives researchers a map of distinct, targetable mechanisms: mitochondrial dysfunction, chronic inflammation, loss of proteostasis, deregulated nutrient sensing, and more. Research peptides are useful here precisely because several map cleanly onto individual hallmarks, letting researchers study each in relative isolation. For the full catalog, see our Best Research Peptides 2026 guide; for metabolic/nutrient-sensing overlap, see our Best Research Peptides for Weight Loss guide. All compounds below are sold strictly for laboratory and in vitro research use.
Skin Biology & ECM Research: GHK-Cu
GHK-Cu (Glycine-Histidine-Lysine Copper) is the most thoroughly published peptide in dermal-aging research, with a literature base tracing back to Dr. Loren Pickart's isolation of GHK from human plasma in the early 1970s. Published fibroblast culture studies document its stimulation of collagen types I, III, and VI, plus elastin and proteoglycan upregulation — the structural proteins whose synthesis declines with age while degradation accelerates. A separate, widely cited line of research (Pickart, Vasquez-Soltero & Margolina, 2012) documented GHK-Cu's modulation of thousands of genes tied to inflammation resolution and antioxidant capacity via Nrf2 pathway activation, the master regulator of the cell's antioxidant enzyme output.
See our GHK-Cu mechanism of action and GHK-Cu in skin & collagen research, or view the GHK-Cu research compound.
Mitochondrial Signaling Research: MOTS-C
MOTS-C is one of the more conceptually significant findings in longevity research from the past decade: a 16-amino-acid peptide encoded within the mitochondrial genome itself, first reported in 2015. Its studied roles include AMPK activation — the cell's primary low-energy sensor, whose responsiveness declines with age — and a proposed function as a messenger relaying mitochondrial stress status to nuclear gene expression. Published research has also found circulating MOTS-C levels decline with age, which is the basis for ongoing interest in whether restoring its signaling affects age-related metabolic decline in research models.
See our MOTS-C mechanism of action and MOTS-C research overview, or view the MOTS-C research compound. A structurally related, cardiolipin-targeted mitochondrial compound, SS-31, is also studied in this space for stabilizing the inner mitochondrial membrane and reducing ROS generation.
Cellular Energy Research: NAD+
NAD+ is a coenzyme rather than a peptide, but its role in aging biology puts it squarely in this category. Every cell requires NAD+ as a cofactor for two aging-relevant enzyme families: sirtuins (SIRT1–7), implicated in longevity and metabolic regulation, and PARPs, which sense and repair DNA damage. Cellular NAD+ levels decline substantially with age in published animal studies, which is the mechanistic basis for research examining whether restoring NAD+ can partially recover sirtuin and PARP activity in aged cell models.
See our NAD+ mechanism of action, NAD+ in cellular research, and the NAD+ vs. NMN vs. NR comparison, or view the NAD+ research compound.
Inflammaging Research: KPV
KPV (Lysine-Proline-Valine) targets "inflammaging" — the persistent, low-grade inflammatory state, marked by elevated IL-6, IL-1β, and TNF-alpha, that's proposed as a shared driver behind cardiovascular, neurodegenerative, and metabolic decline with age. Its studied NF-κB inhibition directly suppresses transcription of those pro-inflammatory cytokines, and its research base in gut and skin models (tissues with high baseline inflammatory tone) makes it a useful tool for studying whether NF-κB suppression shifts aged tissue toward a lower-inflammation state.
See our KPV mechanism of action and KPV research overview, or view the GHK-Cu/KPV research compound.
Neural Longevity Research: Semax & Selank
Cognitive decline is one of the most-studied aspects of biological aging, and both Semax and Selank research centers on BDNF (brain-derived neurotrophic factor), a protein essential for synaptic plasticity and neuronal survival that declines with age. Semax has been studied primarily for BDNF and NGF upregulation in cortical and hippocampal tissue, with its deepest published record in cerebral ischemia neuroprotection. Selank takes a complementary route through anxiolytic and HPA-axis regulatory pathways, relevant given that chronic glucocorticoid excess is itself studied as an accelerant of neural aging.
See our Semax mechanism of action and Selank mechanism of action, or view the Semax and Selank research compounds.
Comparison Table
| Peptide | Primary Hallmark Addressed | Key Studied Mechanism |
|---|---|---|
| GHK-Cu | ECM degradation, epigenetic alterations | Collagen/elastin upregulation, Nrf2 activation |
| MOTS-C | Mitochondrial dysfunction | AMPK activation, mito-nuclear signaling |
| SS-31 | Mitochondrial dysfunction | Cardiolipin stabilization, ROS reduction |
| NAD+ | Deregulated nutrient sensing, genomic instability | Sirtuin & PARP cofactor restoration |
| KPV | Chronic inflammation ("inflammaging") | NF-κB pathway inhibition |
| Semax / Selank | Intercellular communication decline | BDNF/NGF upregulation, HPA-axis modulation |
FAQ
Why use the hallmarks-of-aging framework instead of studying one compound in isolation? Because aging is a multi-pathway process. Mapping each compound to a specific hallmark makes it possible to design research that isolates one mechanism at a time rather than conflating several overlapping effects.
How does GHK-Cu relate to the KLOW stack? GHK-Cu is one of the four components in V8's KLOW research stack alongside BPC-157, TB-500, and KPV — see our KLOW Stack research compound for the full combination.
All compounds referenced are sold for licensed laboratory and in vitro research only, not for human or veterinary use.